Viking Therapeutics, Inc. filed a Form 8-K with the SEC on September 22, 2026, reporting that the company issued a press release announcing top-line results from its maintenance study of GLP-1/GIP agonist VK2735.
Key Highlights
- Top-line results announced: Viking Therapeutics disclosed top-line results from a maintenance study of its GLP-1/GIP agonist VK2735.
- Event date: The press release was issued on September 22, 2026.
- Compound studied: The maintenance study involves VK2735, described in the filing as a GLP-1/GIP agonist.
- Press release filed as exhibit: The full press release is attached as Exhibit 99.1 to the current report and incorporated by reference.
- Signed by CEO: The filing was signed by Brian Lian, Ph.D., President and Chief Executive Officer, as Principal Executive Officer.
Viking Therapeutics Files 8-K on VK2735 Maintenance Study Findings
Viking Therapeutics, Inc. (NASDAQ:VKTX), a Delaware-incorporated biopharmaceutical company headquartered at 9920 Pacific Heights Blvd, Suite 500, San Diego, California 92121, filed a current report on Form 8-K dated September 22, 2026, under Item 8.01 (Other Events). According to the filing, the company issued a press release on that same date announcing top-line results from its maintenance study of VK2735, which the filing identifies as a GLP-1/GIP agonist.
The filing itself does not include the detailed results of the maintenance study. Instead, it states that a copy of the press release, dated September 22, 2026, is filed as Exhibit 99.1 and incorporated into the current report by reference. The filing does not summarize, describe, or quantify the top-line results within the body of the 8-K itself.
The report was signed by Brian Lian, Ph.D., in his capacity as President and Chief Executive Officer and Principal Executive Officer of Viking Therapeutics, Inc. The company's common stock, with a par value of $0.00001 per share, is listed on The Nasdaq Stock Market LLC under the trading symbol VKTX. Viking Therapeutics is not classified as an emerging growth company, according to the filing.
What Was Disclosed
Viking Therapeutics filed an 8-K on September 22, 2026, to report the issuance of a press release containing top-line results from a maintenance study of its GLP-1/GIP agonist VK2735. The press release is attached as Exhibit 99.1.



Please wait processing your request...